Aetiology and outcomes of secondary myelofibrosis occurring in the context of inherited platelet disorders: A single institutional study of four patients

et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOUR): a randomised, phase 3, open label, multicentre study. Lancet Oncol. 2016;17(1):27–38. 4. Dimopoulos M, Wang M, Maisnar V, Minarik J, Bensinger W, Mateos MV, et al. Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study. J Hematol Oncol. 2018;11(1):49. 5. Chari A, Hajje D. Case series discussion of cardiac and vascular events following carfilzomib treatment: possible mechanism, screening, and monitoring. BMC Cancer. 2014;4(14):915. 6. Efentakis P, Kremastiotis G, Varela A, Nikolaou P-E, Papanagnou E-D, Davos CH, et al. Molecular mechanisms of carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of metformin. Blood. 2019;133(7):710–23. 7. Chari A, Stewart K, Russell S, Moreau P, Herrmann J, Banchs J, et al. Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials. Blood Adv. 2018;2(13):1633–44. 8. McCormack T, Boffa RJ, Jones NR, Carville S, McManus RJ. The 2018 ESC/ESH hypertension guideline and the 2019 NICE hypertension guideline, how and why they differ. Eur Heart J. 2019;40(42):3456–8. 9. NICE Guideline NG 136 Hypertension in adults, diagnosis and management, August 2019. 10. Bringhen S, Milan A, D’Agostino M, Ferri C, W€asch R, Gay F, et al. Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib. A consensus paper by the European Myeloma Network and the Italian society of arterial hypertension. J Intern Med. 2019;286(6):3–74.

[1]  W. Ouwehand,et al.  Congenital macrothrombocytopenia with focal myelofibrosis due to mutations in human G6b-B is rescued in humanized mice. , 2018, Blood.

[2]  M. Abu-Farha,et al.  Novel G6B gene variant causes familial autosomal recessive thrombocytopenia and anemia , 2017, European journal of haematology.

[3]  Sylvia Richardson,et al.  A dominant gain-of-function mutation in universal tyrosine kinase SRC causes thrombocytopenia, myelofibrosis, bleeding, and bone pathologies , 2016, Science Translational Medicine.

[4]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[5]  R. Brynes,et al.  Autoimmune myelofibrosis: an update on morphologic features in 29 cases and review of the literature. , 2014, Human pathology.

[6]  F. Passamonti,et al.  CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons , 2014, Leukemia.

[7]  M. Kempers,et al.  A dominant-negative GFI1B mutation in the gray platelet syndrome. , 2013, New England Journal of Medicine.

[8]  A. Borkhardt,et al.  The Thr224Asn mutation in the VPS45 gene is associated with the congenital neutropenia and primary myelofibrosis of infancy. , 2013, Blood.

[9]  S. Watson,et al.  Mice Lacking the ITIM-Containing Receptor G6b-B Exhibit Macrothrombocytopenia and Aberrant Platelet Function , 2012, Science Signaling.

[10]  A. Bertuch,et al.  Clinical, histopathologic, and genetic features of pediatric primary myelofibrosis—An entity different from adults , 2012, American journal of hematology.

[11]  J. Parkinson,et al.  Mutations in NBEAL2, encoding a BEACH protein, cause gray platelet syndrome , 2011, Nature Genetics.

[12]  J. Mullikin,et al.  NBEAL2 is mutated in Gray Platelet Syndrome and is required for biogenesis of platelet alpha-granules , 2011, Nature Genetics.

[13]  Nancy F. Hansen,et al.  Gray platelet syndrome: natural history of a large patient cohort and locus assignment to chromosome 3p. , 2010, Blood.

[14]  P. Nurden,et al.  The gray platelet syndrome: clinical spectrum of the disease. , 2007, Blood reviews.

[15]  J. Viallard,et al.  Reversible myelofibrosis induced by tuberculosis. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  R. Brynes,et al.  Pathology of autoimmune myelofibrosis. A report of three cases and a review of the literature. , 2001, American journal of clinical pathology.